Insights
EditorialJune 20265 min read

Why the way we take medicine matters as much as the medicine itself.

The story of healthcare is usually told through molecules. For the person living it, what matters is something quieter, and often decisive.

By the Arc editorial team

The story of healthcare is usually told through molecules. For the person living it, what matters is something quieter, and often decisive.

Almost all of the attention, funding, and prestige in medicine flows toward one moment: discovery. The identification of a target, the design of a molecule, the trial that proves it works. It is thrilling work, and it deserves the applause it receives.

But a molecule that works in a trial and a medicine that works in a life are not the same thing. Between them lies a stretch of ordinary human friction, a tablet too large to swallow, a schedule too complex to keep, a taste a child refuses, a routine that collapses on the first difficult day. This friction rarely makes the headlines. It decides almost everything.

Friction is not a footnote

When a treatment is hard to take, people take it less. This is not a failure of willpower or discipline; it is a predictable response to a design that ignored the realities of a human day. For many chronic conditions, the share of people still taking their medicine as prescribed a year later is far lower than the trials that approved it ever assumed.1

The consequences are not abstract. A therapy left in the cabinet does nothing. The gap between what was prescribed and what was actually taken is, quietly, one of the largest sources of waste and harm in modern healthcare.

A breakthrough that no one can take is not yet a medicine.

Designing for the moment of taking

This is the work we chose. Not to replace the science of discovery, but to take seriously the part that comes after it, how a treatment is made, how it is taken, and whether a person can keep it in their life without a fight.

The test we hold everything to is deliberately plain: can a real person live with it? It is a low bar to state and a demanding one to meet. But it is the bar that decides whether a discovery ever becomes a benefit. The molecule will always matter. So does everything that happens the moment it reaches a hand.

References

  1. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Adherence among patients with chronic disease averages around 50% in developed countries. who.int
More perspectives All insights

Keep exploring

On the arc of human discovery.